Technical Analysis for VYGR - Voyager Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 8.45 | -1.39% | -0.12 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | -1.39% | |
| Stochastic Sell Signal | Bearish | -1.39% | |
| Earnings Movers | Other | -1.39% | |
| Overbought Stochastic | Strength | -1.39% | |
| Bearish Engulfing | Bearish | -3.64% | |
| Fell Below 50 DMA | Bearish | -3.64% | |
| Earnings Movers | Other | -3.64% | |
| Weak + Overbought | Other | -3.64% | |
| Weak, Overbought and Reversal Signs | Reversal | -3.64% | |
| Overbought Stochastic | Strength | -3.64% |
| Alert | Time |
|---|---|
| Possible NR7 | less than a minute ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
| Down 1% | about 4 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Voyager Therapeutics, Inc. Description
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Genetics Gene Therapy Parkinson's Disease Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Huntington's Disease Genzyme Monogenic Ataxia Friedreich's Ataxia Neuromuscular Disease Severe Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.3398 |
| 52 Week Low | 6.06 |
| Average Volume | 710,342 |
| 200-Day Moving Average | 8.18 |
| 50-Day Moving Average | 8.84 |
| 20-Day Moving Average | 8.08 |
| 10-Day Moving Average | 8.26 |
| Average True Range | 0.41 |
| RSI (14) | 52.61 |
| ADX | 21.04 |
| +DI | 29.73 |
| -DI | 22.53 |
| Chandelier Exit (Long, 3 ATRs) | 8.02 |
| Chandelier Exit (Short, 3 ATRs) | 8.48 |
| Upper Bollinger Bands | 9.10 |
| Lower Bollinger Band | 7.06 |
| Percent B (%b) | 0.74 |
| BandWidth | 25.16 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.1511 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.10 | ||||
| Resistance 3 (R3) | 9.14 | 9.00 | 9.01 | ||
| Resistance 2 (R2) | 9.00 | 8.86 | 8.98 | 8.98 | |
| Resistance 1 (R1) | 8.78 | 8.78 | 8.71 | 8.75 | 8.95 |
| Pivot Point | 8.64 | 8.64 | 8.61 | 8.62 | 8.64 |
| Support 1 (S1) | 8.43 | 8.51 | 8.36 | 8.39 | 8.19 |
| Support 2 (S2) | 8.29 | 8.42 | 8.27 | 8.16 | |
| Support 3 (S3) | 8.07 | 8.29 | 8.13 | ||
| Support 4 (S4) | 8.04 |
